XML 68 R36.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Accumulated Other Comprehensive Income (Loss) (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Equity [Abstract] |
Schedule of Accumulated Other Comprehensive Income (Loss) | The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:
(In millions) |  | Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Gains (Losses) on Net Investment Hedges, Net of Tax(1) |  | Unrealized gains (losses) on pension benefit obligation, Net of Tax |  | Currency Translation Adjustments |  | Total
Balance, December 31, 2021 |  | $ | (2.2) |  |  | $ | 53.8 |  |  | $ | 25.5 |  |  | $ | (44.8) |  |  | $ | (139.0) |  |  | $ | (106.7) |
Other comprehensive income (loss) before reclassifications |  | (26.4) |  |  | 204.5 |  |  | 12.6 |  |  | 4.2 |  |  | (154.5) |  |  | 40.4 |
Amounts reclassified from accumulated other comprehensive income (loss) |  | 7.4 |  |  | (125.5) |  |  | (38.1) |  |  | — |  |  | 58.9 |  |  | (97.3) |
Net current period other comprehensive income (loss) |  | (19.0) |  |  | 79.0 |  |  | (25.5) |  |  | 4.2 |  |  | (95.6) |  |  | (56.9) |
Balance, September 30, 2022 |  | $ | (21.2) |  |  | $ | 132.8 |  |  | $ | — |  |  | $ | (40.6) |  |  | $ | (234.6) |  |  | $ | (163.6) |
(1) Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.
(In millions) |  | Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Gains (Losses) on Net Investment Hedges, Net of Tax |  | Unrealized gains (losses) on pension benefit obligation, Net of Tax |  | Currency Translation Adjustments |  | Total
Balance, December 31, 2020 |  | $ | 1.4 |  |  | $ | (179.0) |  |  | $ | (8.5) |  |  | $ | (66.3) |  |  | $ | (46.6) |  |  | $ | (299.0) |
Other comprehensive income (loss) before reclassifications |  | (2.5) |  |  | 143.0 |  |  | 35.3 |  |  | 3.9 |  |  | (80.3) |  |  | 99.4 |
Amounts reclassified from accumulated other comprehensive income (loss) |  | 1.1 |  |  | 62.0 |  |  | (0.1) |  |  | — |  |  | — |  |  | 63.0 |
Net current period other comprehensive income (loss) |  | (1.4) |  |  | 205.0 |  |  | 35.2 |  |  | 3.9 |  |  | (80.3) |  |  | 162.4 |
Balance, September 30, 2021 |  | $ | — |  |  | $ | 26.0 |  |  | $ | 26.7 |  |  | $ | (62.4) |  |  | $ | (126.9) |  |  | $ | (136.6) |
Reclassification out of Accumulated Other Comprehensive Income | The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):
(In millions) | Income Statement Location |  | Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)
| For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Gains (losses) on securities available for sale | Other (income) expense |  | $ | (8.0) |  |  | $ | (0.4) |  |  | $ | (9.4) |  |  | $ | (1.3) |
| Income tax benefit (expense) |  | 1.7 |  |  | 0.1 |  |  | 2.0 |  |  | 0.3 |
Gains (losses) on cash flow hedges | Revenue |  | 77.7 |  |  | (14.9) |  |  | 143.2 |  |  | (68.7) |
| Operating expense |  | (0.8) |  |  | (0.3) |  |  | (3.5) |  |  | (0.3) |
| Other (income) expense |  | — |  |  | — |  |  | (0.2) |  |  | 0.1 |
| Income tax benefit (expense) |  | (7.8) |  |  | 1.5 |  |  | (14.0) |  |  | 6.8 |
Gains (losses) on net investment hedges(1) | Other (income) expense |  | — |  |  | — |  |  | 38.1 |  |  | 0.1 |
Currency Translation Adjustments | Other (income) expense |  | — |  |  | — |  |  | (58.9) |  |  | — |
Total reclassifications, net of tax |  |  | $ | 62.8 |  |  | $ | (14.0) |  |  | $ | 97.3 |  |  | $ | (63.0) |
(1) Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss). + References No definition available. + Details
Name: | us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration